Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis

ME. Weinblatt, A. Baranauskaite, J. Niebrzydowski, E. Dokoupilova, A. Zielinska, J. Jaworski, A. Racewicz, M. Pileckyte, K. Jedrychowicz-Rosiak, SY. Cheong, J. Ghil,

. 2018 ; 70 (1) : 40-48. [pub] 20171121

Language English Country United States

Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19013070

OBJECTIVE: SB5 is a biosimilar agent for adalimumab (ADA). The aim of this study was to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of SB5 in comparison with reference ADA in patients with rheumatoid arthritis (RA). METHODS: In this phase III, randomized, double-blind, parallel-group study, patients with moderately to severely active RA despite treatment with methotrexate were randomized 1:1 to receive SB5 or reference ADA at a dosage of 40 mg subcutaneously every other week. The primary efficacy end point was the response rate based on the American College of Rheumatology 20% improvement criteria (ACR20) at week 24 in the per-protocol set (completer analysis). Additional end points included efficacy, PK, safety, and immunogenicity assessments. RESULTS: Of the 544 patients randomized to receive a study drug, the full analysis set comprised 542 patients (269 in the SB5 group, 273 in the reference ADA group) and the per-protocol set comprised 476 patients (239 receiving SB5, 237 receiving reference ADA). The ACR20 response rate at week 24 in the per-protocol set was equivalent between those receiving SB5 and those receiving reference ADA (72.4% and 72.2%, respectively); the difference in the ACR20 response rate (0.1%, [95% confidence interval -7.83%, 8.13%]) was within the predefined equivalence margin (±15%). Similar results were seen in the full analysis set (missing data being considered a nonresponse). The SB5 and reference ADA treatment groups were comparable across other end points, including the ACR 50% and ACR 70% improvement response rates, Disease Activity Score in 28 joints based on the erythrocyte sedimentation rate, PK data, incidence of treatment-emergent adverse events, and the antidrug antibody response. Subgroup analyses showed that the efficacy and safety of SB5 and reference ADA were comparable regardless of antidrug antibody status. CONCLUSION: The ACR20 response rate at week 24 was equivalent between patients treated with the biosimilar agent SB5 and those treated with reference ADA. SB5 and reference ADA were both well tolerated, with comparable safety profiles, in patients with RA.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19013070
003      
CZ-PrNML
005      
20190409155520.0
007      
ta
008      
190405s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/art.40336 $2 doi
035    __
$a (PubMed)28950421
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Weinblatt, Michael E $u Brigham and Women's Hospital, Boston, Massachusetts.
245    10
$a Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis / $c ME. Weinblatt, A. Baranauskaite, J. Niebrzydowski, E. Dokoupilova, A. Zielinska, J. Jaworski, A. Racewicz, M. Pileckyte, K. Jedrychowicz-Rosiak, SY. Cheong, J. Ghil,
520    9_
$a OBJECTIVE: SB5 is a biosimilar agent for adalimumab (ADA). The aim of this study was to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of SB5 in comparison with reference ADA in patients with rheumatoid arthritis (RA). METHODS: In this phase III, randomized, double-blind, parallel-group study, patients with moderately to severely active RA despite treatment with methotrexate were randomized 1:1 to receive SB5 or reference ADA at a dosage of 40 mg subcutaneously every other week. The primary efficacy end point was the response rate based on the American College of Rheumatology 20% improvement criteria (ACR20) at week 24 in the per-protocol set (completer analysis). Additional end points included efficacy, PK, safety, and immunogenicity assessments. RESULTS: Of the 544 patients randomized to receive a study drug, the full analysis set comprised 542 patients (269 in the SB5 group, 273 in the reference ADA group) and the per-protocol set comprised 476 patients (239 receiving SB5, 237 receiving reference ADA). The ACR20 response rate at week 24 in the per-protocol set was equivalent between those receiving SB5 and those receiving reference ADA (72.4% and 72.2%, respectively); the difference in the ACR20 response rate (0.1%, [95% confidence interval -7.83%, 8.13%]) was within the predefined equivalence margin (±15%). Similar results were seen in the full analysis set (missing data being considered a nonresponse). The SB5 and reference ADA treatment groups were comparable across other end points, including the ACR 50% and ACR 70% improvement response rates, Disease Activity Score in 28 joints based on the erythrocyte sedimentation rate, PK data, incidence of treatment-emergent adverse events, and the antidrug antibody response. Subgroup analyses showed that the efficacy and safety of SB5 and reference ADA were comparable regardless of antidrug antibody status. CONCLUSION: The ACR20 response rate at week 24 was equivalent between patients treated with the biosimilar agent SB5 and those treated with reference ADA. SB5 and reference ADA were both well tolerated, with comparable safety profiles, in patients with RA.
650    _2
$a adalimumab $x škodlivé účinky $x farmakokinetika $x terapeutické užití $7 D000068879
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antirevmatika $x škodlivé účinky $x terapeutické užití $7 D018501
650    _2
$a revmatoidní artritida $x farmakoterapie $7 D001172
650    _2
$a biosimilární léčivé přípravky $x škodlivé účinky $x farmakokinetika $x terapeutické užití $7 D059451
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Baranauskaite, Asta $u Lithuanian University of Health Sciences, Kaunas, Lithuania.
700    1_
$a Niebrzydowski, Jaroslaw $u Medica Pro Familia, Gdynia, Poland.
700    1_
$a Dokoupilova, Eva $u Medical Plus, Uherske Hradiste, Czech Republic.
700    1_
$a Zielinska, Agnieszka $u Medica Pro Familia, Warsaw, Poland.
700    1_
$a Jaworski, Janusz $u Reumatika, Centrum Reumatologii, Warsaw, Poland.
700    1_
$a Racewicz, Artur $u Zdrowie Osteo-Medic, Białystok, Poland.
700    1_
$a Pileckyte, Margarita $u Lithuanian University of Health Sciences, Kaunas, Lithuania.
700    1_
$a Jedrychowicz-Rosiak, Krystyna $u Mazowieckie Centrum Badań Klinicznych, Grodzisk Mazowiecki, Poland.
700    1_
$a Cheong, Soo Yeon $u Samsung Bioepis, Incheon, Republic of Korea.
700    1_
$a Ghil, Jeehoon $u Samsung Bioepis, Incheon, Republic of Korea.
773    0_
$w MED00188151 $x 2326-5205 $g Roč. 70, č. 1 (2018), s. 40-48 $t Arthritis & rheumatology (Hoboken, N.J.)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28950421 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190409155535 $b ABA008
999    __
$a ok $b bmc $g 1392380 $s 1051375
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 70 $c 1 $d 40-48 $e 20171121 $i 2326-5205 $m Arthritis & rheumatology $x MED00188151
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Logged in users only

Archiving options